Related Experiment Video

Updated: Jul 17, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative

Maria Roche1, Helena Kyriakou, Michael Seiden

  • 1Massachusetts General Hospital, Division of Hematology and Oncology, 55 Fruit Street, Boston, MA 02114, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|January 11, 2007
PubMed

Insights

Tesetaxel, an oral taxane derivative, showed early promise for treating colorectal and gastric cancers. However, it was discontinued in 2006 due to insufficient demonstrated benefit compared to existing chemotherapy options.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Daiichi Sankyo Co Ltd was developing tesetaxel, an oral semisynthetic taxane derivative.
  • Tesetaxel was investigated for potential treatment of various cancers, including colorectal and gastric cancer.

Purpose of the Study:

  • To evaluate the efficacy and benefit of tesetaxel as a cancer chemotherapy agent.

Main Methods:

  • Clinical development and assessment of tesetaxel's therapeutic benefit.
  • Comparison against existing marketed agents for cancer chemotherapy.

Main Results:

  • Early signs of promise were observed for tesetaxel.
  • Tesetaxel failed to demonstrate clear benefit over current cancer chemotherapy agents.

Conclusions:

  • Tesetaxel was removed from Daiichi Sankyo's development pipeline in November 2006.
  • The drug's development was halted due to a lack of significant advantage over established treatments.

More Related Videos

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...